Cancer Genomics and Precision Medicine

(Code: 4826, 1st – 2nd year, 1 unit)

(Course ID: GS-c4826-L)

1. Instructors

Name	Position	Department	Contact Information
IKEDA Sadakatsu	Professor	Hospital Department of Cancer Center	ikeda.canc@tmd.ac.jp
OKADA Takuya	Associate Professor	Gastrointestinal Surgery	t-okada.srg1@tmd.ac.jp

2. Classroom/Lab Lecture Location

On-demand: on WebClass.

The report assignments will be informed by e-mail.

3. Course Purpose and Outline

[Course Purpose]

Organize a systematic knowledge of the basic to clinical aspects of cancer genomics. [Outline]

The course will cover the fundamentals necessary to understand cancer genomic medicine, cancer gene panel testing as applied in clinical practice, and the signaling pathways and molecular targeted drugs necessary to interpret genetic mutations.

4. Course Objectives

Learn the actual practice of cancer genome diagnostics and apply it to actual clinical practice and research.

5. Format

The subject consists of lectures and report assignments.

All programs are conducted in an omnibus format.

6. Course Details

No.	Topics		
1	Basics of Genetic and genome variant		
2	Basics of next generation sequencers		
3	Data Analysis in cancer genomic profiling tests (1)		
4	Data Analysis in cancer genomic profiling tests (2)		
5	Current Status and Outlook of cancer genomic medicine (1)		
6	Current Status and Outlook of cancer genomic medicine (2)		
7	Treatment option after cancer genomic profiling tests (1)		
8	Treatment option after cancer genomic profiling tests (2)		

7. Assessment

The assessment will be by the report assignments.

8. Prerequisite Reading

None.

9. Reference Materials

None.

10. Language Used

All classes are conducted in English.

11. Office Hours

Mon – Fri: 9:00 AM – 17:00 PM

Contact: IKEDA Sadakatsu, Hospital Department of Cancer Center

E-mail: ikeda.canc@tmd.ac.jp

Please contact the instructor regarding questions or consultations.

12. Note(s) to Students

It is preferable to take this course together with "Advanced Clinical Oncology."